Cisplatinum

DRUG10 trials

Sponsors

University of Arkansas, European Mantle Cell Lymphoma Network, Royal Marsden NHS Foundation Trust, AZ-VUB, The Netherlands Cancer Institute

Conditions

HPV Positive Oropharyngeal Squamous Cell CarcinomaHead and Neck CancerLymphoma, Mantle-CellMantle Cell LymphomaMultiple MyelomaNSCLCNon-Hodgkins LymphomaNon-Small-Cell Lung Carcinoma

Phase 1

Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

AZ-VUBNon-Small-Cell Lung Carcinoma

Start: 2006-11-30End: 2008-04-30Target: 30Updated: 2008-03-13

Phase 2

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

CompletedNCT00083538

University of ArkansasMultiple Myeloma

Start: 2001-02-28End: 2007-12-31Updated: 2010-07-07

Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC

Universität Duisburg-EssenNSCLC

Start: 2012-11-30End: 2015-04-30Updated: 2012-12-05

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

George Washington UniversityHead and Neck Cancer

Start: 2015-06-30End: 2023-12-30Updated: 2023-06-27

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

Shenzhen Hornetcorn Bio-technology Company, LTDNSCLC

Start: 2016-05-31End: 2018-12-31Target: 60Updated: 2016-05-09

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

CompletedNCT02896582

The Lymphoma Academic Research OrganisationMantle Cell Lymphoma

Start: 2016-11-29End: 2024-12-02Updated: 2026-01-14

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

RecruitingNCT03215719

NYU Langone HealthHPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Carcinoma

Start: 2017-10-18End: 2028-12-31Target: 120Updated: 2026-01-06

Phase 3

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

European Mantle Cell Lymphoma NetworkLymphoma, Mantle-Cell

Start: 2004-07-31End: 2014-12-31Target: 360Updated: 2012-09-10

Adaptive Radiation Treatment for Head and Neck Cancer

CompletedNCT01504815

The Netherlands Cancer InstituteHead and Neck Cancer

Start: 2012-09-07End: 2024-12-24Updated: 2025-01-29

Unknown Phase

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

CompletedNCT00301301

Royal Marsden NHS Foundation TrustNon-Hodgkins Lymphoma

Target: 39Updated: 2010-01-12

Related Papers

Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial.

2025-07-10

Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.

2024-11-09

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Blood2024-11-05

<i>Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?</i>

Blood2024-11-05

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood2024-04-2610 citations

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood2023-11-029 citations

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Blood2023-11-023 citations

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.

2023-10-244 citations

Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study).

2023-09-176 citations

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Cancers2021-12-3113 citations

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.

2020-09-2116 citations

Phase II study: Induction chemotherapy & transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): An update and retrospective review of non-study patients.

Journal of Clinical Oncology2020-05-20

[<sup>18</sup>F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials.

2020-04-1817 citations

Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): A novel approach.

Journal of Clinical Oncology2018-05-205 citations

Phase II study: Induction chemotherapy & transoral surgery as definitive tx for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—A novel approach.

Journal of Clinical Oncology2017-05-205 citations

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

2016-06-14280 citations

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Blood2015-05-29154 citations

Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.

2013-02-2286 citations

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

2009-12-23207 citations